Myeloma Paper of the Day, July 21st, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: RPL5 loss, APOBEC mutagenesis, & gain of function structural variants involving MYC & chromothripsis drive daratumumab resistance, as does depletion of CD38+ NK cells, persistent T-cell exhaustion, & reduced depletion of T regs.”
Source: Robert Orlowski/X
Authors: Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin Diamond, Paolo Corradini, David Coffey, Ola Landgren, Niccolò Bolli, Benedetto Bruno, Mario Boccadoro, Massimo Massaia , Francesco Maura, and Alessandra Larocca.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023